Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.

Fern extract a potential adjunct therapy for melasma in Asians

Pearl Toh
14 Apr 2018

Taking the oral extract product of the fern Polypodium leucotomos (PLE) on top of the standard topical hydroquinone cream and sunscreen reduces the severity of melasma to a greater extent compared with the standard treatment alone in Asian patients, a pilot study has shown.

The single-centre, prospective, double-blind study recruited 40 patients (mean age 51 years) diagnosed with melasma and were being treated with a standard topical treatment of 4% hydroquinone cream and sunscreen SPF 50+ at the National Skin Centre in Singapore. They were randomized 1:1 to oral PLE 480 mg twice daily or a placebo for 12 weeks, in addition to receiving standard topical treatment. [J Clin Aesthet Dermatol 2018;11:14-19]

As expected, both the PLE and the placebo arms significantly improved in mMASI* scores compared with baseline (54.9 percent; p0.01 and 44.4 percent; p0.01, respectively), as participants in both arms also received hydroquinone.

However, the reduction in mMASI score was greater in the PLE than the placebo groups, which became significantly different between groups starting from week 8 (percentage reduction, 49.4 percent vs 32.6 percent; p0.05).

“Subjects in the PLE group experienced significant improvement in mMASI scores from the first month of treatment, indicating that PLE accelerates the pigmentation clearance of melasma compared to those treated with topical 4% hydroquinone and sunscreen alone,” observed the researchers led by Dr Goh Chee-Leok from the National Skin Centre.

In addition, more patients in the PLE arm achieved 60 percent improvement in mMASI score than those in the placebo arm (40.0 percent vs 11.8 percent; p=0.066) after 2 months of treatment.

Both arms showed improvement in the erythema and the melanin indices compared with baseline, but the difference between the two groups were not statistically significant.

The melasma quality of life scores (MelasQoL) were also improved in both groups, although the between-group difference was not statistically significant until week 12 (improvement, 14.9 percent vs 11.7 percent; p0.05). The decrease in MelasQoL scores was fourfold greater in the PLE vs the placebo arms as early as week 4.

No major side effects were reported during the study. Mild itching and stinging with the use of hydroquinone cream were reported in two and three patients in the PLE and placebo arms, respectively.

“Our findings indicate that it is an effective co-adjuvant treatment for melasma in combination with topical 4% hydroquinone and sunscreen SPF 50,” said the researchers.

“It should be stressed that PLE should not be used in place of sun protection measures, including use of topical sunscreen and avoidance of sun exposure during the peak hours of the day,” they added, suggesting that further studies on a larger cohort or with a higher PLE dose might show significant effects.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Audrey Abella, 28 Nov 2018
Use of the oral anticoagulant rivaroxaban at a low dose may reduce the risk of thromboembolic events* in patients with heart failure (HF), according to a post hoc analysis of the COMMANDER HF** trial.